<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(1)</volume><submitter>Barnhoorn MC</submitter><funding>Digest Science</funding><pubmed_abstract>&lt;h4>Background and aims&lt;/h4>The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas.&lt;h4>Methods&lt;/h4>A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy.&lt;h4>Results&lt;/h4>Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years.&lt;h4>Conclusions&lt;/h4>Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.</pubmed_abstract><journal>Journal of Crohn's &amp; colitis</journal><pagination>64-70</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6930001</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.</pubmed_title><pmcid>PMC6930001</pmcid><pubmed_authors>Molendijk I</pubmed_authors><pubmed_authors>Fibbe WE</pubmed_authors><pubmed_authors>van der Meulen-de Jong AE</pubmed_authors><pubmed_authors>Peeters KCMJ</pubmed_authors><pubmed_authors>van der Woude CJ</pubmed_authors><pubmed_authors>Roelen DL</pubmed_authors><pubmed_authors>Barnhoorn MC</pubmed_authors><pubmed_authors>Zwaginga JJ</pubmed_authors><pubmed_authors>Hommes DW</pubmed_authors><pubmed_authors>Maljaars PWJ</pubmed_authors><pubmed_authors>Verspaget HW</pubmed_authors><pubmed_authors>Oosten LEM</pubmed_authors><pubmed_authors>Wasser MNJM</pubmed_authors><pubmed_authors>Roelofs H</pubmed_authors><pubmed_authors>Bonsing BA</pubmed_authors><pubmed_authors>Dijkstra G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.</name><description>&lt;h4>Background and aims&lt;/h4>The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas.&lt;h4>Methods&lt;/h4>A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy.&lt;h4>Results&lt;/h4>Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years.&lt;h4>Conclusions&lt;/h4>Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2024-11-11T23:44:21.613Z</modification><creation>2020-05-22T01:16:56Z</creation></dates><accession>S-EPMC6930001</accession><cross_references><pubmed>31197361</pubmed><doi>10.1093/ecco-jcc/jjz116</doi></cross_references></HashMap>